Related references
Note: Only part of the references are listed.Real-World Clinical Outcomes of Crizotinib Treatment in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases
K. L. Davis et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP
Tomohide Tamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Toyoaki Hida et al.
LANCET (2017)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer
Mark K. Doherty et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer
Xiangchan Hong et al.
ONCOTARGET (2017)
Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study
Edmond Bendaly et al.
ADVANCES IN THERAPY (2017)
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Sen Zhang et al.
CLINICAL CANCER RESEARCH (2016)
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis
Kimberly L. Johung et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
Shirish M. Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014
Benjamin J. Solomon et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series
Giulio Metro et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Scott N. Gettinger et al.
LANCET ONCOLOGY (2016)
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong-Wan Kim et al.
LANCET ONCOLOGY (2016)
Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer
Tatsuya Yoshida et al.
LUNG CANCER (2016)
Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
Puyuan Xing et al.
ONCOTARGET (2016)
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
Justin F. Gainor et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
Deepa Rangachari et al.
LUNG CANCER (2015)
Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)
Anita Kort et al.
PHARMACOLOGICAL RESEARCH (2015)
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel et al.
LANCET ONCOLOGY (2014)
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A basic introduction to fixed-effect and random-effects models for meta-analysis
Michael Borenstein et al.
RESEARCH SYNTHESIS METHODS (2010)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Share Paper
